About Cognoa
Cognoa is a leading pediatric behavioral health company leveraging artificial intelligence (AI) to develop digital diagnostics and therapeutics aimed at improving lifelong outcomes for children at risk for developmental delays. Their core mission is to provide earlier, more accurate, and equitable access to care for behavioral health conditions. The company’s flagship product, Canvas Dx, is the first FDA-authorized diagnosis aid designed to assist physicians in diagnosing autism spectrum disorder (ASD) in children aged 1.5 to 6 years within a primary care setting. This innovative solution utilizes AI to process caregiver-provided information and physician inputs, significantly reducing the diagnostic timeline from months or years to days, thereby enabling earlier intervention during a critical neurodevelopmental window.
By addressing the challenges of specialist shortages and diagnostic disparities, Cognoa’s technology aims to democratize access to timely diagnoses, particularly for underserved populations who often face longer delays. Beyond autism, Cognoa is actively expanding its pipeline of digital diagnostic and therapeutic products to address other significant unmet needs in pediatric behavioral health, including Attention-Deficit/Hyperactivity Disorder (ADHD), Attention Deficit Disorder (ADD), and anxiety in children. The company also offers a child development app to parents, often through employer benefits programs, to support and track their child’s developmental health.
Focus Areas
Business Intelligence
| Key Investors | Morningside Group, Monroe Capital, Stanford Technology Ventures Program, 5Y Capital |
| Partnerships | Wyoming Medicaid, Health Transformation Alliance (HTA), Highmark Insurance, EVERSANA, Autism Learning Partners, LEARN Behavioral |
| Technology | AI-powered digital medicine platform, machine learning algorithms, responsible AI, mobile app-based data collection (videos, questionnaires) |
| FDA Clearances | 1 cleared products (estimated) |
What Physicians Need to Know
For physicians, Cognoa's Canvas Dx offers a streamlined, highly accurate, and efficient tool to diagnose or rule out autism in young children (1.5 to 6 years) directly within primary care settings. This empowers pediatricians to respond to early developmental concerns, reducing the reliance on specialists and shortening the time to diagnosis and intervention. The system provides actionable insights and detailed developmental reports, which can save time on documentation and facilitate better communication with families and educators. Its remote assessment capabilities (parent app for videos and questionnaires) offer a family-friendly experience, and the AI's training on diverse data helps mitigate diagnostic disparities. Cognoa also provides support for documentation and reimbursement, making it practical for clinical integration.
Cognoa's technology, primarily Canvas Dx, integrates seamlessly into the diagnostic workflow through a multi-platform approach. Parents/caregivers utilize a mobile app to complete questionnaires and upload short home videos of their child. Clinicians access a web portal to provide their clinical impressions and review the AI-generated developmental profile and diagnostic prediction. This combination of inputs is processed by Cognoa's machine learning algorithm to deliver a comprehensive assessment.
What the Web Says
Cognoa is a healthcare technology company focused on developing AI-powered digital diagnostics and therapeutics for developmental delays, particularly Autism Spectrum Disorder (ASD). Their primary product, the Cognoa ASD Diagnosis Aid (CanvasDx), is an FDA-authorized software as a medical device intended to assist healthcare providers in diagnosing ASD in young children. Reviews indicate that the product is highly accurate and aims to provide earlier and faster diagnoses, addressing a significant unmet need in pediatric care. While product reviews are generally positive, there is limited public information available regarding company culture or employer reviews on platforms like Glassdoor.
Overall: PositiveStrengths
- Highly accurate AI-powered diagnostic tool for ASD.
- Aims to provide earlier and faster autism diagnoses.
- Reduces dependence on narrow, single-signal tests by combining parent input, clinician input, and objective video analysis.
- FDA-authorized and granted breakthrough designation.
- User-friendly mobile app design for parents and caregivers.
- Potential to scale to other neurodevelopmental and behavioral conditions.
Limitations
- Limited public information on company/employer reviews (e.g., Glassdoor).
- The diagnostic aid is not a stand-alone diagnostic device and requires a healthcare provider's input.
- Risks of misdiagnosis or delayed diagnosis due to false positives or negatives, though these appear to be low.
- Some limitations in customization for certain aspects of their learning and development platform (if considering 'Cognota' as a related entity).
Based on reviews from: G2, Glassdoor, Capterra, Reddit, FDA, Contemporary Pediatrics, Future Human, Whit Grove UX, Indeed.com, PitchBook
Last updated: 2026-07-18
Videos
News, demos, and interviews about Cognoa.
Videos load interactively. If none appear, search YouTube for Cognoa →
Press & Coverage
Frequently Asked Questions
Related Companies
e4health is a healthcare consulting and services company that provides innovative solutions to hospitals, health systems, outpatient providers, and physician practices. The company focuses on addressing data, quality, and revenue challenges within the healthcare ecosystem. Their services are designed to streamline health information data and workflows, optimize coding, quality, and clinical documentation integrity processes, and […]
PayZen is a healthcare fintech company that leverages AI and automation to address the growing challenge of healthcare affordability for patients and financial stability for providers. The platform offers personalized, interest-free payment plans, extending up to 60 months, tailored to each patient’s ability to pay. This approach aims to remove financial barriers to care, allowing […]
Healthcare Finance.AI is dedicated to optimizing healthcare revenue cycles through cutting-edge AI technologies. The company aims to improve financial outcomes for healthcare providers while supporting their commitment to quality care and efficiency. Their solutions are designed to enhance revenue cycle efficiency, reduce claim turnaround times, and improve patient billing accuracy. Their platform leverages advanced analytics […]
The American Academy of Family Physicians (AAFP) is one of the largest national medical organizations in the United States, representing over 130,000 family physicians, residents, and medical students. Founded in 1947, its core mission is to improve the health of patients, families, and communities by serving the needs of its members with professionalism and creativity. […]
Imperial College Business School, a faculty of Imperial College London, is a leading institution that integrates business education with science, engineering, medicine, and technology. For physicians and healthcare providers, the Business School offers specialized programs and research focused on the intersection of AI, digital transformation, and healthcare management. Their curriculum is designed to equip healthcare […]
Columbia University, through its online learning initiative ColumbiaX on edX, offers a range of courses, including those focused on healthcare AI. The university is a global leader in research, teaching, and public impact, consistently ranked among top universities. Their online offerings reflect a commitment to academic excellence and expanding access to high-quality education worldwide. For […]